Week of September 27th 2021 | Vol. 10, Issue 39
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
The Centers for Disease Control and Prevention (CDC) announced plans Friday for a $2.1 billion investment into public health infrastructure for infection prevention across healthcare facilities such as hospitals, nursing homes, dialysis clinics and ambulatory surgery centers.

Bankrolled by the American Rescue Plan, the investments are an effort to stem the spread of emerging infectious diseases like COVID-19 and healthcare-associated infections that have surged over the past year, the agency said.

“This funding will dramatically improve the safety and quality of the healthcare delivered in the United States during the pandemic and in the future,” CDC Director Rochelle Walensky, M.D., said in a statement. 
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
9 transactions totaling $4 million
Supplies, Equipment & Services
20 transactions totaling $2,354 million
Healthcare IT & Managed Care
3 transactions totaling $6 million
Healthcare Facilities & Distributors
6 transactions totaling $31 million
Pharma & Biotech
22 transactions totaling $360 million
Supplies, Equipment & Services
24 transactions totaling $1,052million
Healthcare IT & Managed Care
21 transactions totaling $1,608 million
Healthcare Facilities & Distributors
3 transaction totaling $106 million
Pharma & Biotech
14 transactions totaling $428 million
Supplies, Equipment & Services
13 transactions totaling $1,848million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
September 20, 2021 - Fierce Healthcare
The Department of Health and Human Services (HHS) is offering federal resources to protect abortion providers and patients in Texas as well as the rest of the country. The department’s announcement Friday included a list of planned actions like grant support for clinics and legal protections for healthcare workers and pregnant patients. Following the passage of Texas’ Senate Bill 8, otherwise known as the "heartbeat bill," the Biden administration has directed a number of government agencies, including HHS, to find ways to safeguard reproductive rights for Texans.

September 20, 2021 - Fierce Biotech
After gaining high-profile backing from Sanofi last November, French venture firm Jeito Capital has pulled together more partners to close its first fund at 534 million euros ($630 million). That large pool of capital will go toward financing between 12 and 15 European biopharmas and contributes to the mission of CEO and founder Rafaèle Tordjman, M.D., Ph.D., who was tasked by the French government with boosting the biotech ecosystem in the country earlier this summer. Jeito will invest up to $100 million in a portfolio company. 

September 21, 2021 - Fierce Biotech
Smartphones are already being used to read COVID-19 test results, screen for conditions ranging from autism to pancreatic cancer and manage ultrasound wands, cardiac monitors and other medical devices. Soon enough, the iPhone in your pocket could also automatically detect mental health issues like depression, anxiety and cognitive decline—all based on the daily activity data already gathered by the device. Findings from research partnerships that Apple has formed with Biogen and the University of California, Los Angeles (UCLA) are being used to develop algorithms able to assess mental health status.

September 22, 2021 - Fierce Biotech
We all want to be the fungi. Hexagon Bio wants to be the fungi by using those organisms to create new treatments for cancer and infectious diseases, and investors are joining the party with $61 million. That financing adds to the $47 million series A raised nearly a year ago to the day for a genomics database that discovers refined secondary metabolites and protein targets. Secondary metabolites, colloquially known as natural products, are small molecules made by bacteria, fungi and plants. About 49% of FDA-approved small molecule cancer drugs and 73% of antibiotics are derived from these secondary metabolites, Hexagon said at the time of its series A. 
Events Hosted or Attended by Bourne Partners

Dates TBD - Charlotte, NC

October 5, 2021 - Virtual Webinar

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.